Veno occlusive disease: Update on clinical management

World Journal of Gastroenterology

Volumn 13, Issue 29, 2007, Pages 3918-3924

  Senzolo, M ^a,b   Germani, G ^a   Cholongitas, E ^b   Burra, P ^a   Burroughs, Andrew K ^b  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^b ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Defibrotide; Liver transplantation; Transjugular intrahepatic portosystemic shunt; Veno occlusive disease

Indexed keywords

AMINO ACID; ANTITHROMBIN III; ASPARTATE AMINOTRANSFERASE; BUSULFAN; CA 125 ANTIGEN; CARMUSTINE; CREATININE; CYCLOPHOSPHAMIDE; DEFIBROTIDE; GLUTAMINE; GLUTATHIONE; HEPARIN; ORAL CONTRACEPTIVE AGENT; PROSTAGLANDIN E1; PROTEIN C; PYRROLIZIDINE ALKALOID; TERBINAFINE; TISSUE PLASMINOGEN ACTIVATOR; URSODEOXYCHOLIC ACID;

ABSENCE OF SIDE EFFECTS; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CAUSE OF DEATH; CHOLESTATIC HEPATITIS; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CREATININE BLOOD LEVEL; DECOMPRESSION SURGERY; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; DOPPLER ECHOGRAPHY; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG MONITORING; DRUG USE; EDITORIAL; FLUID RETENTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATIC ENCEPHALOPATHY; HEPATOMEGALY; HUMAN; HYPERBILIRUBINEMIA; INCIDENCE; LIVER INJURY; LIVER TRANSPLANTATION; LIVER VENOOCCLUSIVE DISEASE; MONOTHERAPY; MORTALITY; MULTIPLE ORGAN FAILURE; NONMYELOABLATIVE CONDITIONING; NUCLEAR MAGNETIC RESONANCE IMAGING; ORGAN TRANSPLANTATION; PATHOPHYSIOLOGY; PATIENT MONITORING; PATIENT SAFETY; PORTAL HYPERTENSION; PORTOSYSTEMIC ANASTOMOSIS; PROGNOSIS; RADIATION INJURY; RISK FACTOR; SODIUM RESTRICTION; SURVIVAL RATE; TREATMENT CONTRAINDICATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 34547988014     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v13.i29.3918     Document Type: Editorial

References (60)

1. McDonald GB, Sharma P, Matthews DE, Shulman HM, Thomas ED. Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors. Hepatology 1984; 4: 116-122
2. Bearman SI. The syndrome of hepatic veno-occlusive disease after marrow transplantation. Blood 1995; 85: 3005-3020
3. Richardson P, Guinan E. The pathology, diagnosis, and treatment of hepatic veno-occlusive disease: current status and novel approaches. Br J Haematol 1999; 107: 485-493
4. Bras G, Jaliffe DB, Stuart KL. Veno-occlusive disease of the liver with non-portal type of cirrhosis occurring in Jamaica. Arch Pathol 1954; 87: 285-300
5. Zuckerman M, Steenkamp V, Stewart MJ. Hepatic venoocclusive disease as a result of a traditional remedy: confirmation of toxic pyrrolizidine alkaloids as the cause, using an in vitro technique. J Clin Pathol 2002; 55: 676-679
6. DeLeve LD, Shulman HM, McDonald GB. Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (venoocclusive disease). Semin Liver Dis 2002; 22: 27-42
7. Alpert LI. Veno-occlusive disease of the liver associated with oral contraceptives: case report and review of literature. Hum Pathol 1976; 7: 709-718
8. Fajardo LF, Colby TV. Pathogenesis of neo-occlusive liver disease after radiation. Arch Pathol Lab Med 1980; 104: 584-588
9. Kumar S, DeLeve LD, Kamath PS, Tefferi A. Hepatic veno-occlusive disease (sinusoidal obstruction syndrome) after hematopoietic stem cell transplantation. Mayo Clin Proc 2003; 78: 589-598
10. Carreras E, Bertz H, Arcese W, Vernant JP, Tomas JF, Hagglund H, Bandini G, Esperou H, Russell J, de la Rubia J, Di Girolamo G, Demuynck H, Hartmann O, Clausen J, Ruutu T, Leblond V, Iriondo A, Bosi A, Ben-Bassat I, Koza V, Gratwohl A, Apperley JF. Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party. Blood 1998; 92: 3599-3604
11. Lee JH, Choi SJ, Lee JH, Kim SE, Park CJ, Chi HS, Lee MS, Lee JS, Kim WK, Lee KH. Decreased incidence of hepatic veno-occlusive disease and fewer hemostatic derangements associated with intravenous busulfan vs oral busulfan in adults conditioned with busulfan + cyclophosphamide for allogeneic bone marrow transplantation. Ann Hematol 2005; 84: 321-330
12. Sebagh M, Debette M, Samuel D, Emile JF, Falissard B, Cailliez V, Shouval D, Bismuth H, Reynes M. "Silent" presentation of veno-occlusive disease after liver transplantation as part of the process of cellular rejection with endothelial predilection. Hepatology 1999; 30: 1144-1150
13. DeLeve LD, Wang X. Decresce in nitric oxide production contributes to hepatic venoocclusive disease. Hepatology 1999; 30:218A
14. DeLeve LD, Wang X, Kanel GC, Ito Y, Bethea NW, McCuskey MK, Tokes ZA, Tsai J, McCuskey RS. Decreased hepatic nitric oxide production contributes to the development of rat sinusoidal obstruction syndrome. Hepatology 2003; 38: 900-908
15. Jones RJ, Lee KS, Beschorner WE, Vogel VG, Grochow LB, Braine HG, Vogelsang GB, Sensenbrenner LL, Santos GW, Saral R. Venoocclusive disease of the liver following bone marrow transplantation. Transplantation 1987; 44: 778-783
16. McDonald GB, Hinds MS, Fisher LD, Schoch HG, Wolford JL, Banaji M, Hardin BJ, Shulman HM, Clift RA. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 1993; 118: 255-267
17. Toh HC, McAfee SL, Sackstein R, Cox BF, Colby C, Spitzer TR. Late onset veno-occlusive disease following high-dose chemotherapy and stem cell transplantation. Bone Marrow Transplant 1999; 24: 891-895
18. Ben-Ari Z. Ascites after transplantation - a mystery. Liver Transpl 2004; 10: 1221
19. Costa F, Choy CG, Seiter K, Hann L, Thung SN, Michaeli J. Hepatic outflow obstruction and liver failure due to leukemic cell infiltration in chronic lymphocytic leukemia. Leuk Lymphoma 1998; 30:403-410
20. Blostein MD, Paltiel OB, Thibault A, Rybka WB. A comparison of clinical criteria for the diagnosis of veno-occlusive disease of the liver after bone marrow transplantation. Bone Marrow Transplant 1992; 10: 439-443
21. Shulman HM, McDonald SJ, Matthews D, Doney KC, Kopecky KJ, Gauvreau JM, Thomas ED. An analysis of hepatic veno-occlusive disease and centrilobular hepatic degenartion following bone marrow transplantation. Gastroenterology 1980; 79:1178-1191
22. Strasser SI, Mc Donald SJ, Schoch HG,. Severe hepatocellular injury after hematopoietic cell transplant: incidence and etiology in 2136 consecutive patients. Hepatology 2000; 32: 299A
23. Eltumi M, Trivedi P, Hobbs JR, Portmann B, Cheeseman P, Downie C, Risteli J, Risteli L, Mowat AP. Monitoring of veno-occlusive disease after bone marrow transplantation by serum aminopropeptide of type III procollagen. Lancet 1993; 342: 518-521
24. Rio B, Bauduer F, Arrago JP, Zittoun R. N-terminal peptide of type III procollagen: a marker for the development of hepatic veno-occlusive disease after BMT and a basis for determining the timing of prophylactic heparin. Bone Marrow Transplant 1993; 11: 471-472
25. Tanikawa S, Mori S, Ohhashi K, Akiyama H, Sasaki T, Kaku H, Hiruma K, Matsunaga T, Morita T, Sakamaki H. Predictive markers for hepatic veno-occlusive disease after hematopoietic stem cell transplantation in adults: a prospective single center study. Bone Marrow Transplant 2000; 26: 881-886
26. Petaja J, Pitkanen S, Vettenranta K, Fasth A, Heikinheimo M. Serum tumor marker CA 125 is an early and sensitive indicator of veno-occlusive disease in children undergoing bone marrow transplantation. Clin Cancer Res 2000; 6: 531-535
27. Helmy A. Review article: updates in the pathogenesis and therapy of hepatic sinusoidal obstruction syndrome. Aliment Pharmacol Ther 2006; 23: 11-25
28. Lassau N, Auperin A, Leclere J, Bennaceur A, Valteau-Couanet D, Hartmann O. Prognostic value of doppler-ultrasonography in hepatic veno-occlusive disease. Transplantation 2002; 74: 60-66
29. Ghersin E, Brook OR, Gaitini D, Engel A. Color Doppler demonstration of segmental portal flow reversal: an early sign of hepatic veno-occlusive disease in an infant. J Ultrasound Med 2003; 22: 1103-1106
30. Dumont Ch, Lambert M, Van Beers BE. MR imaging findings in a patient with hepatic veno-occlusive disease. Acta Gastroenterol Belg 2004; 67: 236-238
31. Carreras E, Garcia-Pagan JC, Bosch J, Rozman C. Transvenous liver biopsies in marrow transplant recipients. Transplantation 1995; 60: 1375
32. Shulman HM, Gooley T, Dudley MD, Kofler T, Feldman R, Dwyer D, McDonald GB. Utility of transvenous liver biopsies and wedged hepatic venous pressure measurements in sixty marrow transplant recipients. Transplantation 1995; 59: 1015-1022
33. Senzolo M, Burra P, Cholongitas E, Lodato F, Marelli L, Manousou P, Patch D, Sturniolo GC, Burroughs AK. The transjugular route: the key hole to the liver world. Dig Liver Dis 2007; 39: 105-116
34. Bearman SI, Anderson GL, Mori M, Hinds MS, Shulman HM, McDonald GB. Venoocclusive isease of the liver: development of a model for predicting fatal outcome after marrow transplantation. J Clin Oncol 1993; 11: 1729-1736
35. Cholongitas E, Quaglia A, Samonakis D, Senzolo M, Triantos C, Patch D, Leandro G, Dhillon AP, Burroughs AK. Transjugular liver biopsy: how good is it for accurate histological interpretation? Gut 2006; 55: 1789-1794
36. McSweeney PA, Niederwieser D, Shizuru JA, Sandmaier BM, Molina AJ, Maloney DG, Chauncey TR, Gooley TA, Hegenbart U, Nash RA, Radich J, Wagner JL, Minor S, Appelbaum FR, Bensinger WI, Bryant E, Flowers ME, Georges GE, Grumet FC, Kiem HP, Torok-Storb B, Yu C, Blume KG, Storb RF. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001; 97: 3390-3400
37. McCune JS, Gibbs JP, Slattery JT. Plasma concentration monitoring of busulfan: does it improve clinical outcome? Clin Pharmacokinet 2000; 39: 155-165
38. The WT, Beyer W, Pendleton JD. Genetic polymorphisms in glutathione s-transferase and plasminogen activator inhibitor and risk of veno-occlusive disease (VOD). Blood 2000, 96: 390A
39. Poonkuzhali S, Vidya S, Shaji RV. Glutathione S-transferase gene polymorphisin and risk of major undergoing allogeneic bone marrow transplantation. Blood 2001, 98: 852A
40. Essell JH, Schroeder MT, Harman GS, Halvorson R, Lew V, Callander N, Snyder M, Lewis SK, Allerton JP, Thompson JM. Ursodiol prophylaxis against hepatic complications of allogeneic bone marrow transplantation. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998; 128: 975-981
41. Ohashi K, Tanabe J, Watanabe R, Tanaka T, Sakamaki H, Maruta A, Okamoto S, Aotsuka N, Saito K, Nishimura M, Oh H, Matsuzaki M, Takahashi S, Yonekura S. The Japanese multicenter open randomized trial of ursodeoxycholic acid prophylaxis for hepatic veno-occlusive disease after stem cell transplantation. Am J Hematol 2000; 64: 32-38
42. Park SH, Lee MH, Lee H, Kim HS, Kim K, Kim WS, Jung CW, Im YH, Yoon SS, Kang WK, Park K, Park CH, Kim SW. A randomized trial of heparin plus ursodiol vs. heparin alone to prevent hepatic veno-occlusive disease after hematopoietic stem cell transplantation. Bone Marrow Transplant 2002; 29: 137-143
43. Giles F, Garcia-Manero G, Cortes J, Thomas D, Kantarjian H, Estey E. Ursodiol does not prevent hepatic venoocclusive disease associated with Mylotarg therapy. Haematologica 2002; 87:1114-1116
44. Vaughan DE, Plavin SR, Schafer AI, Loscalzo J. PGE1 accelerates thrombolysis by tissue plasminogen activator. Blood 1989; 73: 1213-1217
45. Gluckman E, Jolivet I, Scrobohaci ML, Devergie A, Traineau R, Bourdeau-Esperou H, Lehn P, Faure P, Drouet L. Use of prostaglandin E1 for prevention of liver veno-occlusive disease in leukaemic patients treated by allogeneic bone marrow transplantation. Br J Haematol 1990; 74: 277-281
46. Bearman SI, Shen DD, Hinds MS, Hill HA, McDonald GB. A phase I/II study of prostaglandin E1 for the prevention of hepatic venocclusive disease after bone marrow transplantation. Br J Haematol 1993; 84: 724-730
47. Goringe AP, Brown S, O'Callaghan U, Rees J, Jebb S, Elia M, Poynton CH. Glutamine and vitamin E in the treatment of hepatic veno-occlusive disease following high-dose chemotherapy. Bone Marrow Transplant 1998; 21: 829-832
48. Strasser SI, McDonald GB. Gastrointestinal and hepatic complications. In: Forman SJ, Blume KG, Thomas ED, editors. Hematopoietic Cell Transplantation. 2nd ed. Oxford: Blackwell Publishing, 1998
49. Lee JH, Lee KH, Choi JS, Zang DY, Kim SB, Kim SW, Suh C, Lee JS, Kim WK, Lee YS, Kim SH. Veno-occlusive disease (VOD) of the liver in Korean patients following allogeneic bone marrow transplantation (BMT): efficacy of recombinant human tissue plasminogen activator (rt-PA) treatment. J Korean Med Sci 1996; 11: 118-126
50. Bearman SI, Shuhart MC, Hinds MS, McDonald GB. Recombinant human tissue plasminogen activator for the treatment of established severe venocclusive disease of the liver after bone marrow transplantation. Blood 1992; 80: 2458-2462
51. Leahey AM, Bunin NJ. Recombinant human tissue plasminogen activator for the treatment of severe hepatic veno-occlusive disease in pediatric bone marrow transplant patients. Bone Marrow Transplant 1996; 17: 1101-1104
52. Bearman SI, Lee JL, Baron AE, McDonald GB. Treatment of hepatic venocclusive disease with recombinant human tissue plasminogen activator and heparin in 42 marrow transplant patients. Blood 1997; 89: 1501-1506
53. Morris JD, Harris RE, Hashmi R, Sarnbrano JE, Gruppo RA, Becker AT, Morris CL. Antithrombin-III for the treatment of chemotherapy-induced organ dysfunction following bone marrow transplantation. Bone Marrow Transplant 1997; 20: 871-878
54. Richardson PG, Elias AD, Krishnan A, Wheeler C, Nath R, Hoppensteadt D, Kinchla NM, Neuberg D, Waller EK, Antin JH, Soiffer R, Vredenburgh J, Lill M, WoolfTey AE, Bearman SI, Iacobelli M, Fareed J, Guinan EC. Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population. Blood 1998; 92: 737-744
55. Chopra R, Eaton JD, Grassi A, Potter M, Shaw B, Salat C, Neumeister P, Finazzi G, Iacobelli M, Bowyer K, Prentice HG, Barbui T. Defibrotide for the treatment of hepatic veno-occlusive disease: results of the European compassionate-use study. Br J Haematol 2000; 111: 1122-1129
56. Mor E, Pappo O, Bar-Nathan N, Shaharabani E, Shapira Z, Tur-Kaspa R, Ben-Ari Z. Defibrotide for the treatment of veno-occlusive disease after liver transplantation. Transplantation 2001; 72: 1237-1240
57. Boyer TD, Haskal ZJ. The role of transjugular intrahepatic portosystemic shunt in the management of portal hypertension. Hepatology 2005; 41: 386-400
58. Senzolo M, Cholongitas E, Patch D, Burroughs AK. TIPS for veno-occlusive disease: is the contraindication real? Hepatology 2005; 42: 240-241; author reply 241
59. Senzolo M, Patch D, Cholongitas E, Triantos C, Marelli L, Stigliano R, Dhillon A, Burroughs A. Severe venoocclusive disease after liver transplantation treated with transjugular intrahepatic portosystemic shunt. Transplantation 2006; 82: 132-135
60. Fried MW, Connaghan DG, Sharma S, Martin LG, Devine S, Holland K, Zuckerman A, Kaufman S, Wingard J, Boyer TD. Transjugular intrahepatic portosystemic shunt for the management of severe venoocclusive disease following bone marrow transplantation. Hepatology 1996; 24: 588-591